A new relationship between FDA and the Department of Defense (DOD) went official Friday (Nov. 2) with the announcement of a memorandum of agreement (MOU) that will formalize a framework agreed upon in January, under which FDA will work with DOD to accelerate access to medical products for the military. The agreement came the same day that FDA approved a highly controversial fentanyl product, which DOD helped develop and said was a high priority drug for the battlefield. FDA now...